{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:27:37Z","timestamp":1777728457608,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T00:00:00Z","timestamp":1377216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To model the estimated disease-modifying effect of etanercept over sulphasalazine in patients with ankylosing spondylitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A post hoc analysis of data from the Ankylosing Spondylitis Study Comparing ENbrel and Sulfasalazine Dosed Weekly (ASCEND) study was performed using the Natural History Staggered Start (NHSS) method. A mixed model with a linear effect over time was fitted to the ASCEND data and resampling was performed to generate confidence intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>At week 16, the total additional improvement in Bath Ankylosing Spondylitis Metrology Index of the etanercept arm over the sulphasalazine arm was 0.62 points, of which 31% (0.19 points) was estimated to be due to disease-modifying effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The analysis of ASCEND data suggests that etanercept may have a larger disease-modifying effect than sulphasalazine. Further research is needed with more objective measures such as magnetic resonance imaging or X-radiography to confirm these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0300060513496171","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T21:35:19Z","timestamp":1377293719000},"page":"1606-1611","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Disease-modifying effect of etanercept versus sulphasalazine on spinal mobility in patients with ankylosing spondylitis"],"prefix":"10.1177","volume":"41","author":[{"given":"Suzanne","family":"Hendrix","sequence":"first","affiliation":[{"name":"Pentara Corporation, Salt Lake City, UT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Koenig","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhi","family":"Li","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amitabh","family":"Singh","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,8,23]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"1694","article-title":"Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index","volume":"21","author":"Jenkinson TR","year":"1994","unstructured":"Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994; 21: 1694\u20131698.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20575"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.30223"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1742"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2005.09.005"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.258"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199601031-00009"},{"key":"e_1_3_3_9_2","first-page":"S10","article-title":"Slowing the progression of Alzheimer disease: methodologic issues","volume":"11","author":"Leber P","year":"1997","unstructured":"Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord 1997; 11(Suppl 5): S10\u2013S21.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70677-9"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-009-9123-2"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1718"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2006.07.001"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2007.04.159"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2007.04.157"},{"key":"e_1_3_3_16_2","volume-title":"SAS\/STAT\u00ae 9.2. User's guide","author":"SAS Institute Inc","year":"2008","unstructured":"SAS Institute Inc. SAS\/STAT\u00ae 9.2. User's guide, Cary, NC: SAS Institute Inc, 2008."},{"key":"e_1_3_3_17_2","unstructured":"Annex 1: summary of product characteristics [Enbrel 25 mg powder] http:\/\/www.enbrel.eu\/Portals\/10\/Enbrel_25mg_SPC_normal.pdf. (accessed 11 May 2012)."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198510040-00001"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060513496171","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0300060513496171","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060513496171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:52:09Z","timestamp":1777459929000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0300060513496171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,23]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1177\/0300060513496171"],"URL":"https:\/\/doi.org\/10.1177\/0300060513496171","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,23]]}}}